[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-myeloblastic-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-myeloblastic-leukemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100612179","determination-of-epigenetic-markers-of-acute-myeloblastic-leukemia-in-elderly-patients-100612179",false,"NCT07250217","Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients","Collection of Biological Samples for Research Purposes: Determination of Epigenetic Markers of Acute Myeloblastic Leukemia in Elderly Patients","LAMME","1. \u002F Control Group\n\n   Inclusion Criteria:\n   * Age ≥ 60 years;\n   * Scheduled for cardiac surgery involving sternotomy;\n   * Normal blood count within the two months preceding sampling;\n   * Affiliated with, or beneficiary of, a social security system;\n   * Written informed consent to participate in the study.\n\n   Exclusion Criteria:\n   * Patients deemed unsuitable for sampling by the surgeon performing the procedure;\n   * Patients under legal protection measures;\n   * Patients under judicial supervision or deprived of liberty by judicial or administrative decision;\n   * Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV).\n2. \u002F AML Group\n\nInclusion Criteria:\n\n* Age ≥ 60 years;\n* Diagnosis of de novo AML or AML secondary to myelodysplastic syndrome, scheduled to receive azacitidine-based treatment;\n* Affiliated with, or beneficiary of, a social security system;\n* Written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Diagnosis of a hematologic disease other than AML;\n* Clinical signs suggestive of active central nervous system leukemia, or presence of isolated extramedullary leukemia;\n* Previous treatment for AML other than hydroxyurea;\n* Severe comorbidities that could interfere with the study, as assessed by the principal investigator;\n* Presence of positive virological markers indicating active infection (hepatitis B, hepatitis C, or HIV);\n* Patients under legal protection;\n* Patients under judicial supervision or deprived of liberty by judicial or administrative decision.",true,"ALL","60 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","The main objective of this study is to identify epigenetic markers specific to abnormal myeloid cells in patients with acute myeloid leukemia (AML) by analyzing the methylation of circulating cell-free DNA in plasma.",[28],"Acute Myeloblastic Leukemia",[28,30,31,32,33],"Methylome","Epigenetic markers","Bone marrow","Diagnosis","RECRUITING","2026-02-03",{"date":37,"type":38},"2026-02-04","ACTUAL",{"date":40,"type":38},"2026-01-13",{"date":42,"type":22},"2027-12-01",{"name":44,"class":45},"Groupe Hospitalier de la Region de Mulhouse et Sud Alsace","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100594186","phase-4-ciprofloxacin-vs-ceftazidime-for-empirical-treatment-of-high-risk-neutropenic-fever-in-children-with-hematologic-malignancies-100594186","NCT07016165","Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Malignancies","Ciprofloxacin Versus Ceftazidime as Empirical Therapy of High-Risk Neutropenic Fever in Children With Hematologic Malignancies : A Randomized Controlled Trial","Inclusion Criteria:\n\n* Children aged 0 to 18 years with hematological malignancies.\n* Children with high-risk neutropenic fever, namely children with blood malignancies induction phase ALL, consolidation phase ALL, reinduction phase ALL, relapse ALL; meningeal ALL, AML, and NHL, diagnosed by a competent pediatrician on duty.\n* Consent from parents to be included in the study.\n\nExclusion Criteria:\n\n* Children with malignancies but accompanied by comorbidities (HIV infection, septic shock).\n* Allergy to ciproloxacin or ceftazidime.\n* Fever associated with blood transfusion reactions.\n* Receiving other antibiotics since 72 hours before being included in the study, except for cotrimoxazole prophylaxis for the prevention of Pneumocystis carinii pneumonia, and ciproloxacin prophylaxis in AML.\n* Children with blood malignancies who have impaired renal function (serum creatinine ≥ 1.5 times the upper normal limit) and impaired liver function (SGPT \\> 5 times the upper normal limit).","18 Years",{"count":55,"type":22},120,[57],"PHASE4","This clinical trial will compare use of ciprofloxacin and ceftazidime work in treating high-risk fever in children with hematological malignancies\n\n1. Does ceftazidime work better than ciprofloxacin as a first-choice antibiotic for children with hematological malignancies who have high-risk fever from low neutrophil count?\n2. Are there any specific factors that affect how children with hematological malignancies respond to ciprofloxacin or ceftazidime when treating high-risk fever?\n\nParticipants in this study are children with hematological malignancies who have a high risk of fever due to low neutrophil count. Children, aged 0 to 18 years old, will be hospitalized between June and December 2025 at Sardjito General Hospital\n\nThe study will involve:\n\n* Collecting patient history, conducting physical exams, and performing supporting tests.\n* Randomly assigning participants into two groups: one group will receive the standard treatment with intravenous ciprofloxacin, while the other group will receive the intervention treatment with intravenous ceftazidime.\n* Both groups will be monitored for various outcomes, including the length of fever, length of low white blood cell count, length of hospital stay, length of antibiotic use, any changes in antibiotics, and mortality.",[60,61,28,62],"Neutropenic Fever","Acute Lymphoblastic Leukemia","Non Hodgkin Lymphoma",[64,65,66,61,28,62],"ciprofloxacin","ceftazidime","neutropenic fever","2025-08-18",{"date":69,"type":38},"2025-08-22",{"date":71,"type":38},"2025-06-01",{"date":73,"type":22},"2025-12-31",{"name":75,"class":45},"Gadjah Mada University",1]